NCT03173599View on ClinicalTrials.gov

The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Chronic Hepatitis B
Interventions
DRUG

PNA 40mg

The beginning dose is 40mg.

DRUG

PNA 80mg

The single dose is 80mg.

DRUG

PNA 160mg

The single dose is 160mg.

DRUG

PNA 240mg

The single dose is 240mg.

DRUG

PNA 360mg

The single dose is 360mg.

DRUG

PNA 480mg

The single dose is 480mg.

DRUG

PNA Placebo

The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.

Trial Locations (1)

Unknown

Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
lead

Guangzhou Yipinhong Pharmaceutical CO.,LTD

INDUSTRY

NCT03173599 - The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter